Cannabis Operator Trulieve Plummets After Legal Setback Delays Federal Rescheduling Decision
Trulieve Cannabis stock fell 14% after a Drug Enforcement Administration administrative law judge paused the cannabis rescheduling case following a Government Accountability Office report raising questions about the drug scheduling process. The delay is significant because moving marijuana to Schedule III would eliminate Section 280E tax penalties that currently force cannabis operators to pay tax on near-gross-profit levels rather than actual earnings, a change analysts viewed as highly accretive to profitability. The DEA has until October 13 to decide whether to reopen the hearing record, and further delays risk pushing any rescheduling decision past November midterm elections.
The pause in federal rescheduling proceedings stems from a Government Accountability Office examination of how drugs are classified, which opponents of moving cannabis to Schedule III leveraged to request a delay. The DEA administrative law judge's decision to halt the case means uncertainty now extends through mid-October, when regulators must determine whether to reopen the full hearing record for additional testimony and evidence.
The tax code's Section 280E provision creates a significant competitive disadvantage for cannabis businesses compared to other industries. By prohibiting expense deductions for companies selling Schedule I or II substances, operators face tax bills calculated against near-gross revenue rather than net profit—a structural burden that Schedule III reclassification would eliminate.
A delay in cannabis rescheduling affects multiple stakeholder groups with competing interests. Public investors holding cannabis stocks face prolonged uncertainty about earnings potential and cash flow prospects, potentially affecting retirement and investment portfolios. Cannabis operators may experience extended pressure on profitability under current tax treatment. Conversely, those opposing rescheduling—including law enforcement groups or pharmaceutical interests—may view additional regulatory deliberation as protecting existing policy frameworks. The outcome could reshape the economic viability of the emerging legal cannabis industry.